Literature DB >> 28491549

Extensive atrial fibrosis in a patient with systemic lupus erythematosus and atrial fibrillation.

Elena Costanza Dal Piaz1, Giulia Casagranda2, Daniele Ravanelli3, Massimiliano Marini1, Aldo Valentini3, Maurizio Del Greco4.   

Abstract

Entities:  

Keywords:  3D, 3-dimensional; AF, atrial fibrillation; Atrial fibrillation; Atrial fibrosis; DE-MRI, delayed enhancement–magnetic resonance imaging; LA, left atrium/atrial; Magnetic resonance imaging; SLE, systemic lupus erythematosus; Systemic lupus erythematosus

Year:  2015        PMID: 28491549      PMCID: PMC5419331          DOI: 10.1016/j.hrcr.2015.02.014

Source DB:  PubMed          Journal:  HeartRhythm Case Rep        ISSN: 2214-0271


× No keyword cloud information.

Introduction

KEY TEACHING POINTS Extensive atrial fibrosis was detected by delayed enhancement–magnetic resonance imaging in a patient with systemic lupus erythematosus and atrial fibrillation with no other cardiovascular risk factors. To our knowledge, atrial fibrosis has not been previously reported in systemic lupus erythematosus or in other autoimmune diseases. The presence of an uncommon thickening of the left atrial wall is frequently found in storage disorders such as amyloidosis. Delayed enhancement–magnetic resonance imaging helps to make a differential diagnosis. The reduced atrial functionality could be interpreted as a predictor of cardiovascular events. The study of left atrial (LA) fibrosis with delayed enhancement–magnetic resonance imaging (DE-MRI) is an established technique that provides a noninvasive means of detecting the electroanatomic substrate of atrial fibrillation (AF). We present a case of a middle-aged woman with systemic lupus erythematosus (SLE) and persistent AF who had extensive atrial fibrosis as detected by DE-MRI before the ablation procedure.

Case Report

In October 2010, a 46-year-old woman was admitted to our cardiology department for an ablation procedure of symptomatic persistent AF. She had SLE since 1990, which started as articular and then became renal involvement (diffuse proliferative glomerulonephritis, class IV) and was treated with steroid therapy, cyclosporine, and cyclophosphamide bolus. All therapies were discontinued in 2006 because of a complete remission of the disease. No cardiovascular risk factor was present, in particular no family history of cardiomyopathy. She was symptomatic for impaired functional status, and she was refractory to pharmacological treatment with antiarrhythmic drugs of class 1C. The echocardiogram revealed normal dimensions of the left ventricle with overall normal systolic function. The LA was moderately enlarged, and the right atrium was only slightly enlarged. Mild mitral regurgitation was found. Before the ablation procedure, she underwent MRI with atrial fibrosis detection (DE-MRI), as reported previously. DE-MRI was performed with a 1.5-T scanner (MAGNETOM Avanto, Siemens Medical Systems, Erlangen, Germany) 15 minutes after a bolus injection of 0.1 mmol/kg of gadobenate dimeglumine (MultiHance, Bracco Spa, Milan, Italy) using a 3-dimensional (3D) inversion recovery prepared, respiration navigated, ECG-gated, gradient echo pulse sequence with fat saturation (Gradient Echo 3-dimensional Inversion Recover Turbo Flash). The axial DE-MRI images revealed massive delayed enhancement in different regions of the LA (see the Online Video), including anterior wall (Figure 1A), posterior wall, and septum (Figure 1B). The percentage of fibrosis relative to the volume of the LA wall was 40%. Furthermore, a significant homogeneous thickening distribution of the atrial wall was present (measured thickness 6.8 mm). The maximum LA volume and LA emptying fraction were 38 ml/mq and 47%, respectively. The DE imaging performed using a 2D inversion recovery sequence after contrast injection demonstrated a small area of fibrosis in the inferolateral mid-wall ventricular myocardium.
Figure 1

Two-dimensional slice from the delayed enhancement–magnetic resonance imaging scan shows massive delayed enhancement in the anterior (A) and posterior (B) walls of the left atrium. An electroanatomic map shows large patches of low bipolar voltage (<0.05 mV) in the anterior wall and septum (C), interspersed with electrically abnormal tissue (0.0 5 mV < bipolar voltage <1 mV) in the posterior wall and roof (D).

During the electrophysiological study (CARTO3, Biosense Webster, Inc., Diamond Bar, CA), the endocardial electroanatomic map of the LA confirmed large areas of low bipolar voltage (<0.05 mV) in the anterior wall and septum (Figure 1C) and an area of electrically abnormal tissue (0.05 mV < bipolar voltage <1 mV) in the posterior wall and roof (Figure 1D). The percentage of fibrosis relative to the LA surface estimated by using the CARTO3 system was 52%. The ablation procedure was performed without complications; nevertheless, during follow-up, the patient had recurrences of atrial tachycardia. SLE is an inflammatory autoimmune disease that can virtually affect all organ systems. Cardiovascular involvement occurs frequently (58%–77%). The most common cardiac manifestations include pericarditis (~25% of all patients with SLE),6, 7 myocarditis, coronary artery disease, valvular lesion such as valvular thickening and regurgitation, and Libman-Sacks endocarditis (prevalence 11%–74%). In the context of cardiac arrhythmias, sinus tachycardia (50% of patients), AF, and atrial ectopic beats are the most frequent. All types of atrioventricular blocks, intraventricular conduction disturbances, and sick sinus syndrome are also observed.12, 13 Very little is known about the pathogenesis of cardiac manifestations in SLE. Histological features of SLE cardiomyopathy include initially inflammatory cell infiltrates and, as the disease advances, myocardial necrosis, fibrotic replacement, and scarring.14, 15 Cases of intramural and subepicardial ventricular fibrosis detected by DE-MRI have been described in the literature. In addition, in other inflammatory autoimmune and vasculitic diseases, DE-MRI most frequently detected a midwall ventricular fibrosis, probably owing to a combination of subclinical inflammatory and immunological processes, while a mosaic patchy distribution of myocardial fibrosis is a pathognomonic feature of systemic sclerosis and recently all ventricular patterns (subendocardial, subepicardial, intramural, and transmural) are observed in these diseases. Nevertheless, to of our knowledge, atrial fibrosis has not been previously reported in SLE or other autoimmune diseases. However, the study of atrial fibrosis using DE-MRI is recent and not widely implemented in the clinical setting of patients with AF. Herein, we also highlight the following peculiar features of this case: The occasional feedback of a significant thickening of the atrial wall in a patient with SLE and AF, a finding of DE-MRI that is frequently detected in storage disorders, such as amyloidosis, that have a known etiopathogenetic mechanism. DE-MRI helped us make a differential diagnosis between these abnormalities. The extension of atrial fibrosis by at least 40% compared to the volume of the LA wall, as evidenced by DE-MRI. It is known that atrial fibrosis with an increase in extracellular matrix deposition results in intra-atrial conduction disturbances (ie, anisotropy and zigzag conduction), thus creating a substrate for AF.19, 20 These findings are matched to a given reduced atrial functionality that could be interpreted as a predictor of cardiovascular events.3, 21, 22 In conclusion, in a patient with SLE with no other cardiovascular risk factors, the presence of an uncommon thickening of the LA wall associated with an extensive atrial fibrosis could, in our opinion, justify the refractoriness of AF. The important question that needs to be answered is whether SLE leads to atrial fibrosis, and other studies are necessary to confirm a correlation between them.

KEY TEACHING POINTS

Extensive atrial fibrosis was detected by delayed enhancement–magnetic resonance imaging in a patient with systemic lupus erythematosus and atrial fibrillation with no other cardiovascular risk factors. To our knowledge, atrial fibrosis has not been previously reported in systemic lupus erythematosus or in other autoimmune diseases.

The presence of an uncommon thickening of the left atrial wall is frequently found in storage disorders such as amyloidosis. Delayed enhancement–magnetic resonance imaging helps to make a differential diagnosis.

The reduced atrial functionality could be interpreted as a predictor of cardiovascular events.

  22 in total

1.  Myocardial disease in systemic vasculitis and autoimmune disease detected by cardiovascular magnetic resonance.

Authors:  N C Edwards; C J Ferro; J N Townend; R P Steeds
Journal:  Rheumatology (Oxford)       Date:  2007-05-03       Impact factor: 7.580

Review 2.  Cardiac manifestations in systemic sclerosis.

Authors:  Sevdalina Lambova
Journal:  World J Cardiol       Date:  2014-09-26

Review 3.  Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases.

Authors:  P M Seferović; A D Ristić; R Maksimović; D S Simeunović; G G Ristić; G Radovanović; D Seferović; B Maisch; M Matucci-Cerinic
Journal:  Rheumatology (Oxford)       Date:  2006-10       Impact factor: 7.580

Review 4.  Molecular determinants of cardiac fibroblast electrical function and therapeutic implications for atrial fibrillation.

Authors:  Lixia Yue; Jia Xie; Stanley Nattel
Journal:  Cardiovasc Res       Date:  2010-10-20       Impact factor: 10.787

Review 5.  Cardiac involvement in systemic rheumatic diseases: An update.

Authors:  Piercarlo Sarzi-Puttini; Fabiola Atzeni; Roberto Gerli; Elena Bartoloni; Andrea Doria; Tatiana Barskova; Marco Matucci-Cerinic; Simona Sitia; Livio Tomasoni; Maurizio Turiel
Journal:  Autoimmun Rev       Date:  2010-08-06       Impact factor: 9.754

6.  Left atrial function predicts heart failure hospitalization in subjects with preserved ejection fraction and coronary heart disease: longitudinal data from the Heart and Soul Study.

Authors:  Christine C Welles; Ivy A Ku; Damon M Kwan; Mary A Whooley; Nelson B Schiller; Mintu P Turakhia
Journal:  J Am Coll Cardiol       Date:  2012-02-14       Impact factor: 24.094

Review 7.  Cardiovascular manifestations of systemic lupus erythematosus: current perspective.

Authors:  A Ansari; P H Larson; H D Bates
Journal:  Prog Cardiovasc Dis       Date:  1985 May-Jun       Impact factor: 8.194

8.  A novel skeleton based quantification and 3-D volumetric visualization of left atrium fibrosis using late gadolinium enhancement magnetic resonance imaging.

Authors:  Daniele Ravanelli; Elena Costanza dal Piaz; Maurizio Centonze; Giulia Casagranda; Massimiliano Marini; Maurizio Del Greco; Rashed Karim; Kawal Rhode; Aldo Valentini
Journal:  IEEE Trans Med Imaging       Date:  2013-11-11       Impact factor: 10.048

9.  Detection and quantification of left atrial structural remodeling with delayed-enhancement magnetic resonance imaging in patients with atrial fibrillation.

Authors:  Robert S Oakes; Troy J Badger; Eugene G Kholmovski; Nazem Akoum; Nathan S Burgon; Eric N Fish; Joshua J E Blauer; Swati N Rao; Edward V R DiBella; Nathan M Segerson; Marcos Daccarett; Jessiciah Windfelder; Christopher J McGann; Dennis Parker; Rob S MacLeod; Nassir F Marrouche
Journal:  Circulation       Date:  2009-03-23       Impact factor: 29.690

10.  Libman-Sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution.

Authors:  Ioannis Moyssakis; Maria G Tektonidou; Vassilios A Vasilliou; Michael Samarkos; Vassilios Votteas; Haralampos M Moutsopoulos
Journal:  Am J Med       Date:  2007-07       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.